| Mifepristone: new preparation. Avoids or facilitates cervical dilatation before vacuum aspiration of pregnancy. | |
| | |
MedLine Citation:
|
PMID: 11824427 Owner: HSR Status: MEDLINE |
Abstract/OtherAbstract:
|
(1) Cervical softening with prostaglandins or laminaria before vacuum aspiration of pregnancy can avoid or facilitate mechanical dilatation. (2) Mifepristone is now licensed in France for cervical softening before vacuum aspiration of pregnancy. (3) The clinical file on mifepristone in this indication contains data from about 20 comparative clinical trials using surrogate end points, namely the need for and/or ease of cervical dilatation. (4) In these trials the cervix was easier to dilate in women who received mifepristone than in women who received a placebo. (5) A few comparative trials showed comparable efficacy of prostaglandins, laminaria (small hydrophilic stents inserted into the cervix that gradually swell, leading to cervical dilatation) and mifepristone in this indication. (6) Before vacuum aspiration, metrorrhagia occurred more frequently in women on mifepristone than in those on a placebo. Blood losses during vacuum aspiration were comparable in women who had received prostaglandins and those who had received mifepristone. (7) The incidence of abdominal pain may be lower on mifepristone than with laminaria or prostaglandins. |
| | |
Authors:
|
- |
Related Documents
:
|
10746847 - Cervical intraepithelial neoplasia in pregnancy. 17688627 - Blue rubber bleb nevus syndrome: report of a patient with hemangiomas of the vaginal po... 2227067 - The pin-hole cervical os; a small fertility problem. 8503707 - Cervical pregnancy. a case report. 3803557 - Adolescent pregnancy in the united states: an interstate analysis. 16293767 - Up-regulation of rat myometrial phospholipases c{beta}1 and c{beta}3 correlates with in... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Prescrire international Volume: 10 ISSN: 1167-7422 ISO Abbreviation: Prescrire Int Publication Date: 2001 Oct |
Date Detail:
|
Created Date: 2002-02-01 Completed Date: 2002-03-28 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9439295 Medline TA: Prescrire Int Country: France |
Other Details:
|
Languages: eng Pagination: 135-40 Citation Subset: T |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Abortifacient Agents, Nonsteroidal
/
adverse effects,
therapeutic use Abortion, Induced / methods Cervical Ripening / drug effects* Cervix Uteri / drug effects* Clinical Trials as Topic Dilatation* / methods Female France Hormone Antagonists / adverse effects, therapeutic use Humans Laminaria Mifepristone / adverse effects, therapeutic use* Misoprostol / adverse effects, therapeutic use Pregnancy Prostaglandins / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Abortifacient Agents, Nonsteroidal; 0/Hormone Antagonists; 0/Prostaglandins; 59122-46-2/Misoprostol; 84371-65-3/Mifepristone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Venlafaxine and generalised anxiety disorder: new preparation. Minimise recourse to drugs.
Next Document: Sibutramine: new preparation. Slight weight loss; but also a slight rise in blood pressure ...